Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating
Arcutis Biotherapeutics CFO Sells Shares Worth Over $110,000
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)
Express News | New Data Shows Zoryve® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
Express News | Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of May 22, 2025